Cimicifuga racemosa

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note

[formulation clarification]

Info: products generally standardized to 1 mg triterpene glycosides

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

infertility in patients of childbearing potential

[Insufficient Evidence]

Dose: 120 mg PO qd on days 1-12 of menstrual cycle; Info: used with clomiphene given on days 3-7 of menstrual cycle

menopausal symptoms

[Possibly Effective]

Dose: 8-128 mg/day PO divided qd-bid; Alt: 20 mg PO q12h

menstrual migraine prophylaxis

[Insufficient Evidence]

Dose: 25 mg PO bid; Info: used with soy isoflavones and dong quai

osteoarthritis

[Insufficient Evidence]

Dose: 70 mg PO qd

osteoporosis

[Insufficient Evidence]

Dose: 40 mg PO qd

rheumatoid arthritis

[Insufficient Evidence]

Dose: 70 mg PO qd

sexual dysfunction

[Insufficient Evidence]

Dose: 20 mg PO q12h